 |
26 Diseases |  |
7 Trials |
|
7 Trials |  |
4331 News |  |
| «12...89101112131415161718...5051» |
- |||| icosapent ethyl / Generic mfg.
Clinical: With regards to AF and OM3 (specifically Icosapent ethyl, DHA has no proven benefit in CVD nor combo epa/dha), one ways CVD reduction (RR ⬇️25%, 17% vs 22%) in appropriate cohort. AF in placebo 3.9% (159) vs IPE 5.3% (215). CVD benefit is much more clear to me. (Twitter) - Jan 30, 2022
- || Nexletol (bempedoic acid) / Esperion Therap, Otsuka, icosapent ethyl / Generic mfg.
I’m still wary of it without outcome trial. Same with Bempedoic Acid. What are the thoughts on holding on the fish oils due to Afib until the Prominent trial comes out? Strength lowered triglycerides the same amount as Vascepa but no benefit? (Twitter) - Jan 30, 2022
- |||| icosapent ethyl / Generic mfg.
1) DOES VASCEPA HELP WITH COVID? ➡️ A trial called MITIGATE is currently studying this. 2) WHAT IS MITIGATE? ➡️ The below 55 minute clip answers it 👇 https://t.co/fbDjdvPDi9 3) WHEN WILL THE TRIAL RESULTS BE PRESENTED? ➡️On April 3 at #ACC22 @DLBHATTMD @VietHeartPA $AMRN (Twitter) - Jan 29, 2022
- || Review, Journal: Umbrella Review on Non-Statin Lipid-Lowering Therapy. (Pubmed Central) - Jan 29, 2022
The European Commission has also recently approved inclisiran for treatment of hypercholesterolemia and mixed hypercholesterolemia even though FDA has put the approval of this drug on hold...Approval of bempedoic acid alone or in combination with ezetimibe has provided additional oral lipid-lowering drug alternatives to ezetimibe. Various lipid-lowering drug targets are under investigation.
- ||| icosapent ethyl / Generic mfg.
🚨 @mmillermd1 @VPrasadMDMPH @NBSaphierMD @P_McCulloughMD @FLSurgeonGen @JamesTodaroMD @RepGregMurphy @MartyMakary @BudoffMd @ACCinTouch @American_Heart @GeoWizz_ @Amarincorp @AlbertBourla @pfizer @SABOURETCardio @BaoGTran #VASCEPA (Twitter) - Jan 29, 2022
- || icosapent ethyl / Generic mfg.
Then I asked Dr Nissen if I should put him on Vascepa as well and hahaaha wow all I have to say lol. (Twitter) - Jan 29, 2022
- icosapent ethyl / Generic mfg.
A Pragmatic Randomized Trial Of Icosapent Ethyl For High Cardiovascular Risk Adults (mitigate) In An Era Of Coronavirus Disease 2019 (Main Tent, Hall D) - Jan 28, 2022 - Abstract #ACC2022ACC_5325;
Various lipid-lowering drug targets are under investigation. Abstract is embargoed at this time.
- icosapent ethyl / Generic mfg.
NATIONAL PATTERNS OF ELIGIBILITY AND USE OF NOVEL LIPID LOWERING THERAPIES IN THE UNITED STATES (Prevention and Health Promotion Moderated Poster Theater 4_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_5083;
Background: The emergence of PCSK9 inhibitors (PCSK9i) and icosapent ethyl (IPE) has expanded the role of lipid lowering therapies beyond statins... Over 10 million US adults would benefit from PCSK9i and IPE, but a vast majority have not been optimally treated with statins.
- icosapent ethyl / Generic mfg.
ICOSAPENT ETHYL REDUCES CARDIOVASCULAR RISK SUBSTANTIALLY AND CONSISTENTLY REGARDLESS OF WAIST CIRCUMFERENCE (eAbstract site) - Jan 28, 2022 - Abstract #ACC2022ACC_5081;
IPE significantly reduced CV events in patients regardless of baseline waist circumference. These data suggest that the benefits of IPE in patients with elevated triglycerides are independent of the degree of baseline abdominal obesity.
- icosapent ethyl / Generic mfg.
EICOSAPENTAENOIC ACID (EPA) DECREASES ANGIOTENSIN CONVERTING ENZYME (ACE) EXPRESSION IN VASCULAR AND PULMONARY ENDOTHELIUM FOLLOWING CYTOKINE CHALLENGE (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_5017;
EPA significantly decreased endothelial expression of ACE in pulmonary and vascular tissues that correlated with reduced release of a leukocyte adhesion molecule. This limited expression of proinflammatory proteins by EPA in multiple vascular beds during inflammation may contribute to reduced CV risk as demonstrated in large outcome trials.
- icosapent ethyl / Generic mfg.
EICOSAPENTAENOIC ACID (EPA) INCREASES HEME OXYGENASE-1 EXPRESSION IN MACROPHAGES AND ENDOTHELIAL CELLS DURING INFLAMMATION (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_5016;
Under conditions of inflammation, EPA significantly increased endothelial expression of HO-1 in EC from multiple tissues and in macrophages. These broad changes in protein expression for EPA during inflammation may contribute to preserved vascular EC function and reduced CV risk demonstrated in large outcome trials.
- icosapent ethyl / Generic mfg., milrinone / Generic mfg.
A PRESENTATION OF DELAYED MYOCARDITIS AFTER CORONAVIRUS DISEASE-2019 (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_2564;
He had history of hypertriglyceridemia on icosapent ethyl and reported no other febrile illness...He was treated with milrinone, diuretics, and guideline directed cardiomyopathy medications were initiated... In conclusion, clinicians should remain vigilant of potential delayed cardiac complications seen in COVID-19 such as delayed myocarditis.
- colchicine / Generic mfg., icosapent ethyl / Generic mfg.
EICOSAPENTAENOIC ACID (EPA) REDUCES J774 MACROPHAGE ACTIVATION AND CYCLOOXYGENASE (COX-1) EXPRESSION (Special Topics Moderated Poster Theater 5_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_956;
EPA reduced LPS-induced macrophage activation, COX-1 levels and iNOS activity in a concentration-dependent manner distinct from colchicine. The beneficial effects of EPA on muted macrophage activation may contribute to the reduced CV risk of EPA treatment demonstrated in human cardiovascular outcome trials.
- ezetimibe / Generic mfg., icosapent ethyl / Generic mfg.
NON-HISPANIC BLACK AND AFRICAN AMERICAN (NHB/AA) PATIENTS: UNDERREPORTED AND UNDERREPRESENTED IN RANDOMIZED CONTROLLED TRIALS OF LIPID LOWERING THERAPY (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_368;
NHB/AAs are underrepresented, and results are underreported in LLT RCTs. An informed clinician patient discussion should include acknowledgement of these limitations in shared decision-making.
- atorvastatin / Generic mfg., icosapent ethyl / Generic mfg.
EICOSAPENTAENOIC ACID (EPA) COMBINED WITH HIGH INTENSITY STATINS REDUCE LIPID OXIDATION IN MODEL MEMBRANES (Poster Hall_Hall C) - Jan 28, 2022 - Abstract #ACC2022ACC_193;
EPA significantly reduced lipid oxidation in the presence of high intensity statins in a concentration-dependent fashion. The antioxidant effects for EPA may contribute to its benefits in statin-treated CV patients as evidenced in clinical outcome trials.
- ||| icosapent ethyl / Generic mfg.
Key differences in inclusion criteria between MITIGATE (M) & PREPARE-IT (P) 👇 ESTABLISHED ASCVD M ✅️ P ❌️ AGE M > 50 P > 18 & > 40 DURATION ON VASCEPA M > 180 days P = 28 & 60 days @DLBHATTMD @VietHeartPA @mmillermd1 @drpablocorral @Amarincorp $AMRN #ACC22 @ACCinTouch (Twitter) - Jan 27, 2022
- ||| icosapent ethyl / Generic mfg.
While we await the results of Dr. Mason's studies, here's a visual; the Generic Vascepa (gV) is in yellow. In addition, many have reported that that gV smells like rotten fish, while Vascepa has a mild, to no scent. My guess is the difference is oxidation due to encapsulation. (Twitter) - Jan 27, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical: I know generic Vascepa you speak of is the prescription version but like so many generics they apply the basic minimum to get by the FDA. Hence they produce as in this case a far inferior drug as compared to the name brand. Again I reiterate do the color and smell test. (Twitter) - Jan 27, 2022
- || icosapent ethyl / Generic mfg.
This is not the OTC version. This is a generic prescription version since Vascepa patent was invalidated https://t.co/i0JfnjRadS (Twitter) - Jan 27, 2022
- || icosapent ethyl / Generic mfg.
I would not for two reasons. One if you compare the color differences between the two you can see the generic is very yellow and Vascepa very clear. Also cut one open and you can smell the difference where generic smells like fish which means it is oxidized and Vascepa no smell. (Twitter) - Jan 27, 2022
- || icosapent ethyl / Generic mfg.
It has DHA in it and you will see it in the rise of your cholesterol and basicly proven useless by the STRENGTH study run by Astazeneca. Only Vascepa is the real deal with proven results. (Twitter) - Jan 27, 2022
- || icosapent ethyl / Generic mfg.
It has DHA in it and you will see it in the rise of your cholesterol and basicly proven useless by the STRENGTH study run by Astazeneca. Only Vascepa is the real deal with proven results. (Twitter) - Jan 27, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical: Has anyone been using generic version of Vascepa (icosapent ethyl)? Should we assume generic has similar efficacy to Vascepa? @DLBHATTMD @mmillermd1 @EliotBrinton @kewatson @jctardif_mhi @CBallantyneMD (Twitter) - Jan 27, 2022
- ||| Praluent (alirocumab) / Sanofi, Regeneron, icosapent ethyl / Generic mfg., vupanorsen (AKCEA-ANGPTL3-LRx) / Ionis, Pfizer
Clinical, Late-breaking abstract: The ACC Late-Breaking Clinical Lipid Trials on Sun April 3, 2022 in DC @ACCinTouch MITIGATE: Icosapent Ethyl in High CV Risk TRANSLATE-TIMI 70: Vupanorsen on non HDL Chol 🇨🇭PACMAN AMI: Alirocumab in AMI w IC imaging APOLLO Trial: siRNA Targeting Lp[a] https://t.co/ZhLStD9Qsf… (Twitter) - Jan 26, 2022
- | ezetimibe / Generic mfg., icosapent ethyl / Generic mfg.
Journal: The Role of Lipid-Lowering Treatment in the Secondary Prevention of Ischemic Stroke. (Pubmed Central) - Jan 26, 2022
Selected patients who do not achieve LDL-C targets despite statin/ezetimibe combination are candidates for receiving proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Finally, it appears that adding icosapent ethyl might also reduce cardiovascular morbidity in patients who have achieved LDL-C targets but have persistently elevated triglyceride levels.
- |||| icosapent ethyl / Generic mfg.
🚨 Does #VASCEPA help with #COVID? Looks like we may find out on Apr 3 at #ACC22 @ACCinTouch Estimated primary completion of #MITIGATE trial is Feb 28 ⚪️Vascepa ≠ 🟡Generic-Vascepa @DLBHATTMD @VietHeartPA @BudoffMd @mmillermd1 @TerraPharma1 $AMRN @P_McCulloughMD @Amarincorp (Twitter) - Jan 26, 2022
- ||| icosapent ethyl / Generic mfg.
🟡Generic Vascepa vs ⚪️Vascepa @DLBHATTMD @mmillermd1 @VietHeartPA @BudoffMd @FLSurgeonGen @NBSaphierMD $AMRN @US_FDA @GeoWizz_ https://t.co/4GTa8miKG7 (Twitter) - Jan 23, 2022
- ||| icosapent ethyl / Generic mfg.
Your 👁 👁 don't lie, not all 💊 are equal. ⚪️ Vascepa (25% RRR, p .00000001) 🟡 Generic Vascepa (UNTESTED) ⚪️≠🟡 📸: Zara12 Fillers, oxidation, purity, encapsulation, 7-yr CVOT all matter! @DLBHATTMD @mmillermd1 @VietHeartPA @BudoffMd @FLSurgeonGen @NBSaphierMD $AMRN (Twitter) - Jan 23, 2022
- ||| icosapent ethyl / Generic mfg.
Weekly Vascepa scripts 👇 Because the Generics have gamed the system and defeated $AMRN's VHTG (MARINE) patents, @Amarincorp stopped promoting Vascepa in the 🇺🇸 End result: 🔽 people take #Vascepa 🔼 CVD & death @DLBHATTMD @DrJBhattacharya @VietHeartPA @BudoffMd @mmillermd1 (Twitter) - Jan 22, 2022
- || icosapent ethyl / Generic mfg.
Clinical, Journal: Icosapent ethyl: safely reducing cardiovascular risk in adults with elevated triglycerides. (Pubmed Central) - Jan 20, 2022
It is prescribed at a dose of 2 grams twice daily and is indicated in patients at high cardiovascular risk who have fasting or non-fasting triglyceride levels ≥150 mg/dl despite maximally tolerated statin treatment, or in individuals with triglyceride levels ≥500 mg/dl. Conversely, n-3 fatty acid medications containing a combination of eicosapentaenoic acid and docosahexaenoic acid are not indicated for reduction of cardiovascular risk and should be actively deprescribed.
- | icosapent ethyl / Generic mfg., dasatinib / Generic mfg.
New P1/2 trial, Metastases: Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body (clinicaltrials.gov) - Jan 19, 2022
P1/2, N=18, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| icosapent ethyl / Generic mfg.
Reimbursement: Vascepa reduces stroke by 28% and heart attacks by 31%. It is criminal what these insurance companies do. @mmillermd1 @DLBHATTMD @VietHeartPA @BudoffMd @SunnyVMD @NBSaphierMD @JamesTodaroMD $AMRN @American_Heart https://t.co/vliYRKXBUM (Twitter) - Jan 13, 2022
- || icosapent ethyl / Generic mfg.
Are all IPE's the same or is there a difference between Vascepa and generic? (Twitter) - Jan 12, 2022
- | Praluent (alirocumab) / Sanofi, Regeneron, Repatha (evolocumab) / Amgen, Astellas
Journal, HEOR: Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany. (Pubmed Central) - Jan 12, 2022
For primary cardiovascular prevention, a combination therapy of icosapent ethyl plus statin is a cost-effective use of resources compared to statin monotherapy. For secondary prevention, icosapent ethyl, ezetimibe, evolocumab, and alirocumab increase patient benefit at different economic costs.
- ||| icosapent ethyl / Generic mfg.
Clinical: Followup question: Are you using icosapent ethyl in all CAD patients or just in those with elevated TGs? Thanks (Twitter) - Jan 12, 2022
- || icosapent ethyl / Generic mfg.
Doc, any mention of Vascepa in this submission? (Twitter) - Jan 11, 2022
- || icosapent ethyl / Generic mfg.
Now what about primary prevention? If statins are good for that wouldn’t Vascepa work just as well? (Twitter) - Jan 11, 2022
- ||| icosapent ethyl / Generic mfg.
A new combination pill (Vascepa & Statin) is being developed. Statins reduce CVD by 35% and Vascepa reduces CVD by an additional 25% on top of that! @DLBHATTMD @mmillermd1 @BudoffMd $AMRN @VietHeartPA @NBSaphierMD @JamalRanaMD @RepGregMurphy @JamesTodaroMD #cvd (Twitter) - Jan 11, 2022
- || Firsocostat (GS-0976) / Gilead, cilofexor (GS-9674) / Gilead
Clinical, Journal: Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. (Pubmed Central) - Jan 11, 2022
P2
In NASH patients with hypertriglyceridemia treated with CILO and FIR, fenofibrate was safe and effectively mitigated increases in triglycerides associated with ACC inhibition. ClinicalTrials.gov NCT02781584.
- | icosapent ethyl / Generic mfg.
Enrollment closed: MITIGATE: A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (clinicaltrials.gov) - Jan 11, 2022
P4, N=39600, Active, not recruiting, Sponsor: Kaiser Permanente
ClinicalTrials.gov NCT02781584. Recruiting --> Active, not recruiting
- ||| icosapent ethyl / Generic mfg.
New analysis from REDUCE-IT in @JACCJournals led by @nickysinghmd on: Consistency of Benefit of Icosapent Ethyl by Background Statin Type in... https://t.co/DBqbVYS2C3 #CardioTwitter #Cardiology #prevention @mmillermd1 @CBallantyneMD (Twitter) - Jan 11, 2022
- || colchicine / Generic mfg., icosapent ethyl / Generic mfg.
I am not adding colchicine as there are many other better tolerated options for risk reduction such as icosapent ethyl. (Twitter) - Jan 11, 2022
- || icosapent ethyl / Generic mfg.
Maybe check in to Vascepa. Look at the data from @DLBHATTMD . (Twitter) - Jan 10, 2022
- || icosapent ethyl / Generic mfg.
ICYMI: “This key finding offers insight for prescribing physicians that the benefits of icosapent ethyl are not only additive to those of statin therapy, but also appear not to vary by the particular statin used,” @dlbhattmd @ACCinTouch #CardioTwitter https://t.co/Xjbz82wClY (Twitter) - Jan 10, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical: In a new analysis of the REDUCE-IT trial, the treatment effect of #icosapentethyl was consistent across different agents and categories of statins patients were taking @MGHHeartHealth @dlbhattmd @ACCinTouch #CardioTwitter https://t.co/Xjbz82wClY (Twitter) - Jan 10, 2022
- || icosapent ethyl / Generic mfg.
I just read the article and the authors say it was positive using a low dose statin? And the big question is it “EPA”? Or does it have to be modified into “ Icosapent Ethyl “? (Twitter) - Jan 10, 2022
- |||| icosapent ethyl / Generic mfg.
BTW speaking of the brain. You might want to keep an eye on a current Alzheimer's study using VASCEPA called BRAVE-EPA (NCT02719327) which may show that the EPA Brain/Blood barrier doesn't really exist?? (Twitter) - Jan 9, 2022
P2/3
- || icosapent ethyl / Generic mfg., Epanova (eicosapentaenoic acid/docosahexaenoic acid) / AstraZeneca, omega-3 ethylester concentrate / Generic mfg.
I think you're talking about EVAPORATE, which used 4g of Vascepa. Epanova (STRENGTH) & Lovaza did not do any heart imaging. https://t.co/Eq8IfgfcCj (Twitter) - Jan 9, 2022
- ||| icosapent ethyl / Generic mfg.
Clinical, Reimbursement: The only problem I have with this is what about the benefits of DHA for the brain and eyes you would get from the fish? And the Vascepa is far too expensive my insurance won’t cover it and either will my patients. Any other options? (Twitter) - Jan 9, 2022